Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult
patients with advanced pancreatic cancer with DNA repair mutations.